Liquid Array Protein Assay Platform

Information

  • Research Project
  • 7482023
  • ApplicationId
    7482023
  • Core Project Number
    R43AI077249
  • Full Project Number
    1R43AI077249-01A1
  • Serial Number
    77249
  • FOA Number
    PA-07-80
  • Sub Project Id
  • Project Start Date
    3/1/2008 - 17 years ago
  • Project End Date
    8/31/2009 - 15 years ago
  • Program Officer Name
    EDWARDS, MICHAEL W.
  • Budget Start Date
    3/1/2008 - 17 years ago
  • Budget End Date
    8/31/2009 - 15 years ago
  • Fiscal Year
    2008
  • Support Year
    1
  • Suffix
    A1
  • Award Notice Date
    2/13/2008 - 17 years ago
Organizations

Liquid Array Protein Assay Platform

[unreadable] DESCRIPTION (provided by applicant): The aim of this project is to extend application of a novel `liquid array' platform, based on Encoded Sortable Particle (ESP) technology, into the protein assay realm. ESPs are optically-encoded microfabricated particles that can be manipulated using magnetic force. We will adapt our ESP-based liquid array system, which has already been successfully applied in the DNA space, to incorporate antibody-based protein detection assays in Phase I, and we will extend the scope of protein assay coverage in Phase II. Phase I will consist of a 6-plex cytokine detection analysis, while Phase II is intended to accommodate assays of 1000-plex or more. In the protein space the ESP platform has significant advantages in cost, throughput, scalability, ease of use, and flexibility over existing bead-based liquid array and fixed array platforms. ESP technology has broad applicability and should be a valuable tool in the diagnosis, prognosis, and characterization of a variety of disease states, including cancer, heart disease, arthritis and inflammatory diseases, kidney disease, liver disease, allergic responses, and infectious diseases (e.g. HIV). [unreadable] [unreadable] PUBLIC HEALTH RELEVANCE: ESP technology as applied to the protein assay space will provide a broad platform for many different kinds of assays. The ESP platform is intrinsically versatile, and has the potential to be used in basic biomedical research, as well as high-throughput discovery and clinical diagnostics. The ability to control the particles magnetically (in a manner significantly different from magnetic beads) is a significant advantage. This technology should be useful in the diagnosis and prognosis of a variety of disease states, including cancer, heart disease, arthritis and inflammatory diseases, kidney disease, and infectious diseases (e.g. HIV). [unreadable] [unreadable] [unreadable]

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    R43
  • Administering IC
    AI
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    99999
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    855
  • Ed Inst. Type
  • Funding ICs
    NIAID:99999\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    ARRAYOMICS, INC.
  • Organization Department
  • Organization DUNS
    140695847
  • Organization City
    SAN DIEGO
  • Organization State
    CA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    92131
  • Organization District
    UNITED STATES